<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568815</url>
  </required_header>
  <id_info>
    <org_study_id>ESHAP-DLBCL</org_study_id>
    <nct_id>NCT00568815</nct_id>
  </id_info>
  <brief_title>Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)</brief_title>
  <official_title>Phase II Study of Rituximab Combined With ESHAP in Patients With Relapse or Refractory DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with
      ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse
      large B cell lymphoma (DLBCL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The salvage therapy in the patients with DLBCL is still controversial. The investigators
      conducted this study to evaluate the efficacy and tolerability of Rituximab combined with
      ESHAP in the patients with DLBCL. The patients enrolled were defined to be relapsed or
      refractory after the first-line chemotherapy like CHOP or other CHOP-like regimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>every cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Chemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab combined with ESHAP</intervention_name>
    <description>Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5</description>
    <arm_group_label>Chemo</arm_group_label>
    <other_name>R-ESHAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range 18-70 years old

          -  Histological confirmed diffuse large B cell lymphoma

          -  ECOG performance status no more than 2

          -  Life expectancy of more than 3 months

          -  Relapse or refractory after the first-line chemotherapy of DLBCL

          -  No evidence of bone marrow involvement

          -  Normal laboratory values: hemoglobin &gt; 8.0g/dl, neutrophil &gt; 1.5×109/L, platelet &gt;
             80×109/L, serum creatine &lt; 1× upper limitation of normal(ULN), serum bilirubin &lt; 1×
             ULN, ALT and AST &lt; 1.5× ULN

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Serious uncontrolled diseases and intercurrent infection

          -  The evidence of CNS metastasis and bone marrow involvement

          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix

          -  History of allergic reaction/hypersensitivity to rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biyun Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>February 16, 2012</last_update_submitted>
  <last_update_submitted_qc>February 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Ye Guo</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>Rituximab</keyword>
  <keyword>ESHAP</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

